Anthera Pharmaceuticals(OTC) ANTH

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for unmet medical needs. The company is advancing its pipeline, which includes innovative treatments for conditions such as exocrine pancreatic insufficiency and autoimmune diseases.

Products and Services

• Sollpura: Investigational non-porcine pancreatic enzyme replacement therapy
• Blisibimod: Targeting B-cell mediated autoimmune diseases
• Licensing agreements with Amgen, Inc. and Eli Lilly and Company

Growth Outlook

• Pipeline includes therapies in late-stage clinical trials
• Potential market expansion with successful product launches
• Strategic partnerships may enhance research and development capabilities

Financial Highlights

• Recent quarterly revenue of $0, reflecting ongoing development phase
• Trailing twelve months (TTM) net income shows a loss of $44.34 million
• Cash and cash equivalents at $8.09 million as of March 31, 2018

Anthera Pharmaceuticals operates in the biotechnology sector, emphasizing the development of treatments for serious health conditions. The company's lead product, Sollpura, is currently in Phase III clinical trials, indicating significant progress towards potential market entry. Additionally, Blisibimod is being evaluated in Phase II trials, targeting autoimmune diseases, which could address substantial patient needs. Despite the lack of revenue in recent quarters, the company maintains a focus on advancing its clinical pipeline. The financial position, with cash reserves of $8.09 million, provides a foundation for continued research and development efforts. The strategic partnerships with established pharmaceutical companies like Amgen and Eli Lilly may further bolster Anthera's capabilities and market reach. Investors may find interest in Anthera Pharmaceuticals due to its innovative pipeline and potential for growth in the biopharmaceutical landscape. The company's commitment to addressing unmet medical needs positions it as a noteworthy player in the biotechnology industry.